FIELD: biotechnology.
SUBSTANCE: present invention relates to the use of a composition including following peptides of a thyroid-stimulating hormone receptor (hereinafter – TSHR): (i) peptide with an amino acid sequence KKKKYVSIDVTLQQLESHKKK (SEQ ID NO: 1) or a sequence that is at least 95% identical to the sequence SEQ ID NO: 1; and (ii) peptide with an amino acid sequence GLKMFPDLTKVYSTD (SEQ ID NO: 2) or a sequence that is at least 90% identical to the sequence SEQ ID NO: 2.
EFFECT: specified composition is used in the suppression or prevention of the production of auto-antibodies to TSHR in vivo, as well as in the treatment and/or prevention of Grave’s disease.
12 cl, 27 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION | 2015 |
|
RU2728963C2 |
| PEPTIDES | 2014 |
|
RU2676149C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE | 2013 |
|
RU2696566C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF ALZHEIMER-TYPE DEMENTIA | 2013 |
|
RU2811687C2 |
| FUSED PROTEINS OF CARCINOEMBRYONAL ANTIGEN | 2005 |
|
RU2380375C2 |
| USE OF PEPTIDE THAT ENHANCES SECRETION OF SOMATOTROPIC HORMONE AS VACCINE ADJUVANT | 2017 |
|
RU2768134C2 |
| PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2582916C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| METHOD OF USE IN THERAPY | 2010 |
|
RU2579659C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
